Loading...
•
Dec 31, 2024
Orthofix Q4 2024 Earnings Report
Orthofix reported record Q4 2024 results driven by strong execution and focus on profitable growth opportunities.
Key Takeaways
Orthofix reported record fourth quarter net sales of $215.7 million, an increase of 8% compared to the fourth quarter of 2023. The company's net loss was $(29.1) million, with a non-GAAP adjusted EBITDA of $23.9 million.
Record fourth quarter 2024 net sales of $215.7 million, an increase of 8% on a reported and constant currency basis compared to fourth quarter 2023
U.S. Spine Fixation net sales growth of 12% compared to fourth quarter 2023, driven by distribution expansion and further penetration in existing accounts
Record Bone Growth Therapies (BGT) net sales of $63.9 million, representing growth of 9% and BGT Fracture net sales growth of 10% compared to fourth quarter 2023
Record Global Orthopedics net sales of $35.8 million, representing constant currency growth of 18% and U.S. Orthopedics net sales growth of 21% compared to fourth quarter 2023
Orthofix
Orthofix
Orthofix Revenue by Segment
Revenue by Segment
Bone Growth Therapies Revenue
CapyFin.comSpinal Implants, Biologics and Enabling Technologies Revenue
CapyFin.comGlobal Orthopedics Revenue
CapyFin.com Forward Guidance
The Company is providing full-year 2025 guidance. Net sales expected to range between $818 million to $826 million, excluding sales from the discontinued M6 artificial disc product lines and including a negative impact from foreign currency of approximately $4 million. Non-GAAP adjusted EBITDA expected to be $82 million to $86 million. Positive free cash flow expected for full-year 2025, excluding the impact of restructuring charges related to the discontinuation of the M6-C artificial cervical and M6-L artificial lumbar disc product lines.
Positive Outlook
- Net sales expected to range between $818 million to $826 million, excluding sales from the discontinued M6 artificial disc product lines and including a negative impact from foreign currency of approximately $4 million
- The Company’s expected net sales represent implied constant currency growth of 6.5% year-over-year at the midpoint of the range.
- Non-GAAP adjusted EBITDA expected to be $82 million to $86 million.
- This range includes the anticipated impact from the discontinuation of the M6 product lines.
- Positive free cash flow expected for full-year 2025, excluding the impact of restructuring charges related to the discontinuation of the M6-C artificial cervical and M6-L artificial lumbar disc product lines.
Revenue & Expenses
Visualization of income flow from segment revenue to net income